Communication - IIS Aragón

10 January 2025

New article by Luis E. Pablo in the Herald of Aragon: “Fifty thousand eyes”

The Scientific Deputy Director of the IIS Aragón, Luis E. Pablo Júlvez, explains in his new article how the High Resolution Cataract Surgery Unit has been operating since 2013 and has already operated on 50.000 cataracts.
9 January 2025

The Obispo Polanco Hospital in Teruel becomes a university hospital

The Hospital Obispo Polanco is the first to be designated a university hospital in the province of Teruel and joins the other four in Aragon. This is the first step towards the introduction of the Medicine degree in Teruel.
8 January 2025

Eduardo Ruiz Pesini: “In the field of research, vocation, work and study are essential”

In this interview, the IIS Aragón researcher talks about his work leading the 'Mitochondrial Biogenesis and Pathology' group (GIIS050) and the main challenges they face.
7 January 2025

Clinical trial nurses: a hidden job, but essential for the success of studies

Marisa de la Rica and Laura Díez, nurses at the Clinical Research Unit of the IIS Aragón, highlight their work, which is essential but unknown within the profession, as part of the multidisciplinary teams that form clinical trials.
3 January 2025

The first three chapters of “ConoceRte” are now available, an innovative Aragonese podcast on youth mental health

Thanks to the coordination of the IIS Aragón, this project is part of the Research Group on Digital Communication and Information (GICID) of UNIZAR, in collaboration with ASAPME Aragón and sponsored by Johnson & Johnson, with the aim of making mental health treatment in young people and adolescents visible and normal. The first three chapters are now available.
1 January 2025

Key bridge revealed in genetic communication of craniofacial development

A study co-led by the Alicante Institute of Neurosciences has discovered the genes that control cell migration, which is the basis for the development of facial structure. The work opens the way to a better understanding of the genetic causes behind certain congenital diseases.
30 December, 2024

A new drug improves clinical outcomes for patients with advanced breast cancer

A Phase 3 clinical trial demonstrates that the combination of imlunestrant and abemaciclib improves progression-free survival in advanced ER+ HER2- breast cancer, regardless of genomic profile. The compound as monotherapy only shows benefits in patients with mutations in the ESR1 gene.